KDNY
Income statement / Annual
Last year (2022), Chinook Therapeutics, Inc.'s total revenue was $6.13 M,
a decrease of 88.13% from the previous year.
In 2022, Chinook Therapeutics, Inc.'s net income was -$184.62 M.
See Chinook Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$6.13 M
|
$51.63 M
|
$827,000.00
|
$17.26 M
|
$15.09 M
|
$17.24 M
|
$50.68 M
|
$72.98 M
|
| Cost of Revenue |
$1.72 M |
$1.69 M |
$422,000.00 |
$554,000.00 |
$584,000.00 |
$559,000.00 |
$549,000.00 |
$89,000.00 |
| Gross Profit |
$4.41 M |
$49.94 M |
$405,000.00 |
$16.70 M |
$14.50 M |
$16.68 M |
$50.13 M |
$72.89 M |
| Gross Profit Ratio |
0.72 |
0.97 |
0.49 |
0.97 |
0.96 |
0.97 |
0.99 |
1 |
| Research and Development
Expenses |
$141.21 M
|
$96.99 M
|
$36.05 M
|
$17.01 M
|
$75.84 M
|
$89.38 M
|
$87.72 M
|
$58.65 M
|
| General & Administrative
Expenses |
$36.29 M
|
$31.90 M
|
$19.07 M
|
$2.96 M
|
$36.04 M
|
$33.75 M
|
$34.28 M
|
$27.81 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$36.29 M
|
$31.90 M
|
$19.07 M
|
$2.96 M
|
$36.04 M
|
$33.75 M
|
$34.28 M
|
$27.81 M
|
| Other Expenses |
$1.72 M |
$1.69 M |
$422,000.00 |
$299,000.00 |
$3.99 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$179.22 M |
$130.57 M |
$55.54 M |
$19.97 M |
$115.86 M |
$123.13 M |
$122.00 M |
$86.45 M |
| Cost And Expenses |
$179.22 M |
$130.57 M |
$55.54 M |
$19.97 M |
$116.45 M |
$123.69 M |
$122.54 M |
$86.54 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$7.18 M |
$0.00 |
$15,000.00 |
$33,000.00 |
$0.00 |
$0.00 |
$2.22 M |
$494,000.00 |
| Depreciation &
Amortization |
$20.89 M
|
$41.87 M
|
$2.25 M
|
$520,000.00
|
$4.95 M
|
$3.99 M
|
$2.55 M
|
$0.00
|
| EBITDA |
-$164.20 M
|
-$57.17 M
|
-$53.98 M
|
-$19.45 M
|
-$101.36 M
|
-$106.45 M
|
-$71.86 M
|
-$13.56 M
|
| EBITDA Ratio |
-26.79 |
-1.11 |
-65.27 |
-1.13 |
-6.72 |
-6.18 |
-1.42 |
-0.19 |
| Operating Income Ratio
|
-30.2
|
-1.92
|
-67.99
|
-1.16
|
-6.72
|
-6.18
|
-1.42
|
-0.19
|
| Total Other
Income/Expenses Net |
$4.81 M
|
-$170,000.00
|
-$27.40 M
|
-$64.82 M
|
$5.22 M
|
$3.23 M
|
$2.18 M
|
-$25.74 M
|
| Income Before Tax |
-$180.27 M |
-$99.21 M |
-$83.63 M |
-$46.52 M |
-$96.14 M |
-$103.23 M |
-$69.68 M |
-$39.31 M |
| Income Before Tax Ratio
|
-29.42
|
-1.92
|
-101.12
|
-2.7
|
-6.37
|
-5.99
|
-1.37
|
-0.54
|
| Income Tax Expense |
$4.34 M |
$2.09 M |
-$2.00 M |
$332,000.00 |
$783,000.00 |
$11.36 M |
-$21.46 M |
-$99,000.00 |
| Net Income |
-$184.62 M |
-$101.30 M |
-$81.62 M |
-$46.85 M |
-$95.36 M |
-$91.86 M |
-$91.15 M |
-$39.21 M |
| Net Income Ratio |
-30.13 |
-1.96 |
-98.7 |
-2.71 |
-6.32 |
-5.33 |
-1.8 |
-0.54 |
| EPS |
-2.87 |
-2.22 |
-6.2 |
-1.11 |
-0.0012 |
-0.0013 |
-0.0014 |
-0.0009 |
| EPS Diluted |
-2.87 |
-2.22 |
-6.2 |
-1.11 |
-0.0012 |
-0.0013 |
-0.0014 |
-0.0009 |
| Weighted Average Shares
Out |
$64.37 M
|
$45.61 M
|
$13.17 M
|
$42.16 M
|
$78.81 B
|
$72.90 B
|
$65.20 B
|
$44.71 B
|
| Weighted Average Shares
Out Diluted |
$64.37 M
|
$45.61 M
|
$13.17 M
|
$42.16 M
|
$78.81 B
|
$72.90 B
|
$65.20 B
|
$44.71 B
|
| Link |
|
|
|
|
|
|
|
|
